Embedding environmental sustainability into pharma’s DNA
As the climate crisis escalates, so too does scrutiny of how companies are addressing the problems.
The pharmaceutical (pharma) industry’s involvement in environmental issues is multifaceted, with implications for the entire product value chain. From research and development (R&D) and supply chain (procurement, manufacturing, transportation, logistics and other services), to patient engagement, modes of delivery and the disposal of products, all aspects of the process are affected.
Although there are complex challenges to overcome, there are also many opportunities to accelerate the pace of change and unlock new business prospects. To achieve their sustainability ambitions, pharma companies need to undergo a fundamental transformation spearheaded by strong leadership, enhanced collaboration and a willingness to innovate with evidence-based improvement initiatives embedded across the industry.
Download our report
DownloadContacts
Karen Taylor
UK Centre for Health Solutions
Emily May
Life Sciences Insight Lead
James Gregson
UK Life Sciences & Healthcare industry leader
David Rakowski
Product Decarbonisation Lead, Health and Life Sciences